Clinical trial
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune…
NCT06948318 · Takeda, Industry · Recruiting
Key facts
| NCT number | NCT06948318 |
|---|---|
| Title | A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia |
| Official title | A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia |
| Lead sponsor | Takeda, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Immune Thrombocytopenic Purpura (ITP) |
| Intervention type | Drug |
| Interventions | Mezagitamab |
| Enrollment | 150 |
| Start date | Aug 14, 2025 |
| Primary completion | Jul 29, 2029 |
| Completion | Jul 29, 2029 |
| First posted | Apr 29, 2025 |
| Last update posted | Feb 4, 2026 |
| Countries | Australia, Bulgaria, China, Croatia, Hong Kong, Italy, Japan, Netherlands, Poland, South Korea, Spain, Turkey (Türkiye) and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: